Prev Chronic Dis by Hsieh, Hui-Min et al.
PREVENTING  CHRONIC  DISEASE
P U B L I C  H E A L T H  R E S E A R C H ,  P R A C T I C E ,  A N D  P O L I C Y 





A Diabetes Pay-for-Performance Program
and Risks of Cancer Incidence and Death in






Suggested citation for  this  article:  Hsieh HM, He JS,  Shin SJ,
Chiu HC, Lee CT. A Diabetes Pay-for-Performance Program and
Risks of Cancer Incidence and Death in Patients With Type 2





We sought to evaluate the effects of diabetes disease management
through a diabetes pay-for-performance (P4P) program in Taiwan
on risks of incident cancer and mortality among patients with type
2 diabetes.
Methods
We conducted a longitudinal observational cohort study using 3
population-based databases in Taiwan. Using propensity score
matching,  we compared patients with type 2 diabetes who en-
rolled in a P4P program with a similar group of patients who did
not enroll in the in P4P program (non-P4P). Primary end points of
interest were risks of incident cancer and all-cause, cancer-specif-
ic, and diabetes-related mortality. Total person-years and incid-
ence and mortality rates per 1,000 person-years were calculated.
Multivariable Cox proportional hazard models and competing risk
regression were used in the analysis.
Results
Overall, our findings indicated that the diabetes P4P program was
not significantly associated with lower risks of cancer incidence,
but it was associated with lower risks of all-cause mortality (adjus-
ted subdistribution hazard ratio [aSHR], 0.59; 95% confidence in-
terval [CI],  0.55–0.63),  cancer-specific mortality (aSHR, 0.85;
95% CI, 0.73–1.00), and diabetes-related mortality (aSHR, 0.54:
95% CI, 0.49–0.60). Metformin, thiazolidinediones, and α glucosi-
dase inhibitors were associated with lower risks of cancer incid-
ence and cancer-specific mortality.
Conclusion
Our findings provide evidence of the potential benefit of diabetes
P4P programs in reducing risks of all-cause mortality and compet-
ing causes of death attributable to cancer-specific and diabetes-re-
lated mortality among type 2 diabetes patients.
Introduction
Diabetes mellitus and cancer are common, serious global health
problems that contribute substantially to health care costs. A 2014
report from the International Diabetes Federation estimated that
more than 387 million people worldwide have diabetes, and by
2035 this number will rise to 592 million; 4.9 million deaths and at
least US $612 billion in health expenditure resulted from diabetes
in 2014 (1). Diabetes is considered a strong independent predictor
of vascular diseases (2). Growing evidence suggests a possible as-
sociation between diabetes (especially type 2 diabetes) and site-
specific cancer risks (eg, liver, breast, colorectal), as well as can-
cer mortality (3,4).
Although the causal mechanisms for the association between dia-
betes and cancer are not clear, potential risk factors common to
both are recognized, including demographic (age, sex, race/ethni-
city), genetic, and lifestyle-related (obesity, diet, physical activity,
tobacco or alcohol consumption) risk factors. Potential mechan-
isms for a possible biologic link between diabetes and cancer in-
clude insulin resistance, hyperinsulinemia, hyperglycemia, and
chronic inflammation (5,6). Most empirical studies focus on ex-
amining the intervention effect of glucose-lowering medication
therapies (metformin, thiazolidinediones, sulfonylureas) on can-
cer risks or cancer prognosis, which in turn may influence cancer-
specific mortality. However, the results regarding associations
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with cancer risk are mixed (3–5). Additional studies examined
primarily the association between single healthy lifestyle choices
(weight control, healthy diet, physical activity) and the risks of
certain types of cancer (5,7). To the best of our knowledge, few
studies have investigated the extent to which integrated interven-
tions  through a  comprehensive  and multidisciplinary  diabetes
management program might mitigate cancer risks and cancer mor-
tality.
Pay-for-performance (P4P) or value-based purchasing programs
have been embraced by many developed nations as a strategic tool
to stimulate delivery of long-term, multidisciplinary diabetes man-
agement  and to allow investment  of  less  money on incentives
while efficiently improving diabetes care quality (8–10). For ex-
ample, the United Kingdom’s Quality and Outcome Framework
and Australia’s  P4P program pay bonuses to reward improve-
ments in care for diabetes patients (9,11). In Taiwan, a diabetes
P4P program was implemented nationwide by Taiwan’s National
Health Insurance Administration (NHIA) at the end of 2001 to
provide comprehensive diabetes management by following the
American Diabetes Association’s clinical practice guidelines (12).
Comprehensive care through diabetes P4P programs may enhance
quality  of  care  and  prevent  or  delay  vascular  complications
(12,13) or reduce risks of all-cause mortality in patients with dia-
betes (13).  However,  evidence of whether comprehensive dia-
betes care through a P4P program has any effect on incidence of
types of cancer, or competing risks for cancer-specific or diabetes-
related death, is limited.
This study aimed to examine the effects of comprehensive dia-
betes care provided through a nationwide diabetes P4P program in
Taiwan on risks of cancer incidence and mortality among patients
with type 2 diabetes. We hypothesized that modifying lifestyle-re-
lated risk factors with a comprehensive diabetes P4P program or
administration of glucose-lowering medication therapies may pre-
vent or delay incident cancer. We conducted an observational in-
tervention and comparison cohort study using data from 3 longit-
udinal population-based databases in Taiwan to examine the ex-
tent to which the P4P program and other risk factors were associ-
ated with cancer incidence and competing causes of death (cancer-
specific and diabetes-related) in patients with type 2 diabetes who
enrolled in the P4P program compared with a group of diabetes
patients who did not participate.
Methods
A diabetes P4P program was implemented by Taiwan’s NHIA in
2001 to improve the quality of health care for diabetes patients.
The program consists of several features (12). First, patients with
diabetes who have at least 2 outpatient visits within 3 months in
the same health care institution are eligible to enroll in the P4P
program. Second, only physicians who specialize in metabolic dis-
orders or endocrinology or who attend a training program for dia-
betes care are eligible to participate in and voluntarily enroll pa-
tients into this P4P program. Third, medical care teams are expec-
ted to work as coordinated physician-led multidisciplinary teams
adhering  to  the  American  Diabetes  Association’s  clinical
guidelines. Fourth, in addition to regular and usual care, P4P pa-
tients receive extra comprehensive care, including medical history
assessment, physical examination, laboratory evaluation, manage-
ment plan evaluation, self-management and health education. Fi-
nally, participating P4P physicians receive extra incentive pay-
ments in addition to regular physician fees depending on incent-
ive targets for improving process (eg, documented hemoglobin
A1c [HbA1c] or low-density lipoprotein tests) and intermediate
outcomes  (eg,  higher  percentages  of  patients  with  controlled
HbA1c or low-density lipoprotein) (12,14).
Study design and data source
We conducted a longitudinal observational intervention and com-
parison  cohort  study  using  3  population-based  databases  in
Taiwan.  One  database  was  the  2-million-sample  longitudinal
health and welfare database from 2000 through 2010, a nationally
representative  random sample  of  NHIA beneficiaries  in  2005,
from which we obtained information on patient comorbid condi-
tions,  health  provider  characteristics,  and  billing  variables  to
identify patients enrolled in the P4P program. The second was a
database containing death registry data from 2000 through 2010,
which provides accurate death dates and cause-of-death informa-
tion. The third was a national cancer registry, from which we ob-
tained accurate cancer diagnosis data from 1979 through 2010.
The 3 databases were linked with encrypted patient identifiers, and
all data analysis was completed in the Health and Welfare Data
Science Center, the Ministry of Health and Welfare in Taiwan in
2015 and 2016. This study was approved by the institutional re-
view board at Kaohsiung Medical University Hospital.
Study population
Diabetes patients were identified by a primary diabetes diagnosis
code (International Classification of Diseases,  Ninth Revision,
Clinical Modification [ICD-9-CM], code 250) on at least 2 outpa-
tient claims or at least 1 inpatient claim in each year during the pa-
tient identification period from 2003 through 2005. We first ex-
cluded patients with type 1 diabetes (ICD-9-CM codes 250.x1 or
250.x3), because they made up less than 3% of diabetes patients,
and patients aged younger than 18 years on the date of first dia-
betes diagnosis during the patient identification period. Among
eligible diabetes patients, we then identified newly enrolled P4P
patients with at least 2 billing codes with “P14x” (internal code)
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for different office visits in the claims during the patient identifica-
tion period and defined the date of first enrollment as the index
date. We identified non-P4P diabetes patients for the comparison
groups who were not found to be enrolled in the P4P program dur-
ing the patient identification period or the follow-up period. Giv-
en that non-P4P patients lacked P4P enrollment index dates, we
randomly assigned index dates based on the dynamic frequency
distribution of time exposure to the P4P intervention from the P4P
group (15). Using the cancer registry database, we excluded pa-
tients with any cancer diagnosis from the first year of the cancer
registry in 1979 to the index date. Totals of 9,450 P4P and 32,923
non-P4P patients with diabetes were identified.
Propensity score matching (PSM) was used to determine adequate
comparison groups to avoid potential confounding by selection bi-
as and confounding factors. We created propensity scores that pre-
dicted the probability of enrollment into the diabetes P4P program
in a logistic regression model. The PSM caliper matching method
with 1-to-1 match was used to match intervention group with com-
parison group members based on propensity score (16,17). This
approach finds the nearest distance of probabilities for the estim-
ated propensity score to determine the best matches with the smal-
lest  standard deviations  between intervention and comparison
groups. If more than 1 potential comparison group member has the
same propensity score as an intervention group member, the al-
gorithm randomly selects  one for  inclusion in the comparison
group (16,17). We also calculated standardized differences of cov-
ariates between phases, and all differences less than 10% indic-
ated acceptable matching (18). Covariates included demographic
characteristics (age, sex, highest level of education, urban or rural
residence), baseline comorbid conditions (eg, the diabetes com-
plications severity index [DCSI] [19] and chronic illness with
complexity index [CIC] [20]), baseline antidiabetes drug use from
1 year before to the index date, and the most frequent health insti-
tution characteristics (accreditation level and geographic location).
After PSM matching, 9,329 P4P and non-P4P matched pairs were
studied.
Variable definitions
The major end points were risks of cancer incidence and all-cause,
cancer-specific, and diabetes-related mortality, with outcomes for
P4P and non-P4P patients being compared. Overall cancer and
common types of cancer (eg, breast, colorectal, liver) among dia-
betes patients were identified using ICD-9-CM diagnosis codes in
the national cancer registry data. Cancer-specific and diabetes-re-
lated mortality were identified from causes of death based on the
ICD-9 and ICD-10 diagnosis codes in the national death registry
data. We defined diabetes-related death given the major risks of
diabetes complications and prognosis that may cause death, in-
cluding diabetes mellitus, macrovascular complications (eg, cardi-
ovascular, cerebrovascular, and peripheral vascular diseases) and
microvascular complications (eg, nephropathy and neuropathy dis-
eases) (19). To compare groups, we followed each P4P and non-
P4P patient from the index date to the first event date, death date,
or study end date on December 31, 2010, whichever came first.
We then calculated and compared total person-years for each pa-
tient and incidence and mortality per 1,000 person-years between
P4P and non-P4P patients with diabetes given different end points.
Several baseline characteristics that may affect outcomes were in-
cluded as control variables. Patient demographic covariates in-
cluded age, sex, highest level of education, and urban or rural res-
idence. The DCSI and CIC within 1 year before the index date
were used to measure baseline comorbidity. These indexes are fre-
quently used in studies (19,20).  The DCSI has 7 categories of
complications by ICD-9-CM code: cardiovascular complications,
nephropathy,  retinopathy,  peripheral  vascular  disease,  stroke,
neuropathy, and metabolic disorders. The CIC index includes non-
diabetes physical illness complexity, diabetes-related complexity,
and mental illness or substance abuse complexity. We excluded
cancer and diabetes-related complexity when constructing the CIC
index to avoid the duplication of the comorbidity identified by the
DCSI and cancer disease (21). Additionally, we controlled for fre-
quently prescribed antidiabetes medications used during the fol-
low-up period on the basis of the Anatomical Therapeutic Chemic-
al Classification System (ATC codes), measured as 0 or 1 binary
variables for identifying whether metformin (ATC code A10BA),
sulfonylureas  (SUs,  ATC  code  A10BB),  thiazolidinediones
(TZDs, ATC code A10BG), or α glucosidase inhibitors (AGIs,
ATC code A10BF) were prescribed.
Because the P4P program requires health staff to work as a team
and cost structures may differ by health institution, the character-
istics of the most frequently seen health care provider were in-
cluded to identify the resources and capacities of individual health
care  institutions;  characteristics  included  accreditation  levels
(medical center, regional hospital, local hospital, or clinic) and
geographic locations (Taipei, northern area, central area, southern
area, Kao-Ping, or eastern area).
Statistical analysis
In addition to the PSM approach, we used multivariable Cox pro-
portional hazard models to estimate the likelihood of all-cause
mortality  comparing  matched  P4P  and  non-P4P  patients.  We
tested the proportional hazard assumption based on scaled Schoen-
feld residuals after fitting Cox proportional hazard models and
found no evidence that the proportional-hazard assumption was vi-
olated (22). To account for the competing causes of death, cancer-
specific death, and diabetes-related death and for the competing
risks of cancer incidence and death, we created competing risk re-
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gression  models;  we  calculated  subdistribution  hazard  ratios
(SHRs) and 95% confidence intervals (CIs) (23). Potential con-
founding variables (Table 1) were controlled for. Patients were
clustered within matched pairs and health care institutions to con-
trol for unequal error variances across matched pairs and health
care providers. All statistical operations were performed by using
SAS version 9.4  (SAS Institute,  Inc)  and Stata  version SE 13
(StataCorp LP). A P value of less than .05 was considered signific-
ant.
Results
Before PSM 1-to-1 matching,  the P4P group and the non-P4P
group differed significantly (P < .001) by several characteristics
(Table 1). After matching, all baseline characteristics between the
2 matched groups were similar. Of the P4P patients, 48.0% were
men and had a mean age of 60.8 years; 38.6% had an education
level of high school or above, and 46.7% lived in urban areas.
Mean DCSI was 1.16 and mean was CIC 1.09. Baseline antidia-
betes drug use did not differ significantly between P4P and non-
P4P patients. Compared with non-P4P patients, P4P patients re-
ceived more metformin, TZDs, and AGIs during follow-up (P <
.001).
Table 2 compares total person-years and crude cancer incidence
and  mortality  per  1,000  person-years  for  various  end  points
between P4P and non-P4P patients. Risks of overall cancer incid-
ence were not significantly associated with the P4P program but
were associated with use of antidiabetes medication, particularly
metformin (aSHR, 0.58: 95% CI, 0.50–0.67), TZDs (aSHR, 0.78;
95% CI, 0.70–0.86), and AGIs (aSHR, 0.62; 95% CI, 0.55–0.69)
(Table  3).  P4P patients  had lower  risks  of  all-cause  mortality
(aSHR,  0.59;  95%  CI,  0.55–0.63),  cancer-specific  mortality
(aSHR, 0.85; 95% CI, 0.73–1.00), and diabetes-related mortality
(aSHR, 0.54; 95% CI, 0.49–0.60) than non-P4P patients with dia-
betes (Figure).
Figure. Adjusted model results and 95% confidence intervals for the effects of
a  pay-for-performance  program  (P4P)  and  prescribed  antidiabetes
medications on the risks of all-cause, cancer, and diabetes-related mortality in
Taiwan. Competing risk regression models were used to analyze the effects of
P4P and drug effects on risks of cancer-specific and diabetes-related mortality
and  the  adjusted  subdistribution  hazard  ratios  were  calculated.  A  Cox
proportionate hazard model was used to analyze all-cause mortality and the
adjusted hazard ratios  were calculated.  Potential  confounders  that  were
controlled  for  were  age,  sex,  highest  level  of  education,  rural  or  urban
residence, baseline comorbidity (diabetes complications severity index and
chronic  illness  with  complexity),  antidiabetes  drug  use  (metformin,
sulfonylureas, thiazolidinediones, α glucosidase inhibitors), and health care
facility characteristics (accreditation level and geographic regions).
 
Discussion
Recent literature has focused on cancer risk or mortality with vari-
ous diabetes treatments, given the potential biologic link or com-
mon risk factors for the observed associations between type 2 dia-
betes and cancer (3–6). However, studies on the effect of diabetes
control through a comprehensive diabetes P4P program on cancer
risks or mortality were inconclusive (4–6,24). Overall, our find-
ings indicated that the diabetes P4P program was not significantly
associated with lower risks of cancer incidence, but it was associ-
ated with lower risks of all-cause mortality, cancer-specific mor-
tality, and diabetes-related mortality.
With all other variables constant, our findings suggest that the dia-
betes P4P program may be less likely to affect the risk of overall
or specific cancer incidence while several types of glucose-lower-
ing therapies (metformin, TZDs, AGIs) may have a protective ef-
fect, consistent with results of observational studies (25,26). The
nonsignificant association between the P4P program and cancer
incidence might be explained by several reasons. First, compared
with medications that affect the potential biologic link between
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diabetes and cancer risk within a shorter period, medications used
over a longer follow-up period may be required for a comprehens-
ive disease management program to demonstrate reduction in risk.
Second, previous studies found that,  after enrollment,  P4P pa-
tients had significantly more outpatient visits, greater expense, and
higher usage of guideline-recommended services (including pre-
ventive services) than non-P4P patients (21). Thus, P4P patients
may receive more cancer screening tests and have more early can-
cer detection and treatment. The potential effect of a comprehens-
ive disease management program on cancer risk might be mitig-
ated. Future study is suggested to examine the effect of a diabetes
P4P program on incidence of specific cancers.
Alternatively, our findings suggest that the diabetes P4P program
not only has a protective effect on all-cause mortality and dia-
betes-related mortality but also influences cancer-specific mortal-
ity  among incident  cancer  patients.  Cancer  survival  outcomes
among P4P patients might be explained by several reasons. First,
the diabetes P4P program in Taiwan requires participating health
care providers to adhere to the American Diabetes Association’s
clinical practice guidelines. The guidelines are consistent with the
nutrition and physical activity guidelines for cancer survivors sug-
gested by the American Cancer Society, including recommenda-
tions for psychosocial and social assessment and care, preventive
care (vaccinations, screening), lifestyle changes, diet,  physical
activities, and obesity management (27). As studies by Chiao et al
(28) and Calip et al (29) suggested, well diabetes care and glucose
control before cancer diagnosis (colorectal, breast), which per-
sisted after diagnosis, may have moderated the mortality effect of
diabetes in newly diagnosed cancer patients (28,29). Second, in
contrast to the uncertain relationship between glucose-lowering
treatments and cancer incidence, previous studies supported bene-
ficial  effects of antidiabetes medications,  along with glycemic
control, possibly affecting cancer treatments, which may in turn
influence cancer-specific mortality (4,25,29). We observed that
P4P patients tended to have more opportunity to receive oral gluc-
ose-lowering medications (metformin, TZDs, AGIs) than non-P4P
patients during follow-up (all P < .001; Table1). Consistent with
other studies, our study (Figure) indicated that metformin (aSHR,
0.44:  95%  CI,  0.35–0.54),  TZDs  (aSHR,  0.73;  95%  CI,
0.62–0.87), and AGIs (aSHR, 0.72; 95% CI, 0.60–0.85) were as-
sociated with lower risks of cancer-specific mortality in incident
cancer patients.
This study has several limitations. First, given the limitation of our
study data periods in the administrative claims from 2000, we
could not track the number of years since diabetes was diagnosed
or identify whether patients were newly diagnosed. However, we
could track the time of cancer diagnosis through the cancer re-
gistry data set since 1979 as the washout period for exclusion cri-
teria. Second, some unobservable confounders for individual pa-
tients (eg,  lifestyle,  prescription adherence, illness experience,
smoking status, body weight, psychological and social assessment)
were  unavailable  in  the  secondary  database.  Although  these
baseline confounding factors were not part of the study design and
we assumed that all characteristics related to health outcomes in
the P4P program were covered by the measured variables among
P4P and non-P4P patients, caution is necessary when interpreting
the effect of the P4P program on mortality. Third, given our study
design, we observed cancer incidence and mortality events over a
5-year  period.  A greater  effect  might  have been found with  a
longer observation period. Nevertheless, our 5-year observation
period was considered sufficient to evaluate and compare various
quality improvement interventions (30). Finally, the data we used
were obtained from patients with diabetes in Taiwan, so results
may not be generalized to other P4P programs in other countries.
Despite these limitations, this study addressed the issue of wheth-
er  integrated interventions through a comprehensive and mul-
tidisciplinary diabetes P4P program might mitigate cancer risks
and mortality. Compared with patients with diabetes not enrolled
in the P4P program, P4P patients had lower risk of all-cause mor-
tality, cancer-specific mortality, and diabetes-related mortality, but
the groups did not differ in overall risks of incident cancer. Our
findings provide evidence of the potential benefit of diabetes P4P
programs in reducing risks of all-cause mortality and competing
causes of death attributable to cancer-specific and diabetes-related
mortality among type 2 diabetes patients.
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Tables
Table 1. Patient and Health Care Institution Characteristics Among P4P and Non-P4P Patients With Type 2 Diabetes, Taiwan
Variable
Before PSM Matching After PSM Matching
P4P Non-P4P P Value P4P Non-P4P P Value
Standardized
Difference, %a
No. 9,450 32,923 NA 9,329 9,329 NA
Patient Characteristics
Sex, no. (%)b
Male 4,511 (47.7) 16,461 (50.0)
<.001
4,475 (48.0) 4,504 (48.3)
.67
0.62
Female 4,939 (52.3) 16,462 (50.0) 4,854 (52.0) 4,825 (51.7) 0.62
Age, mean (SD), yb 60.7 (11.4) 62.9 (12.1) <.001 60.8 (11.4) 60.7 (12.3) .62 0.93
Age category, no. (%), y
<55 3,039 (32.2) 9,152 (27.8)
<.001
2,966 (31.8) 3,229 (34.6)
<.001
5.99
55–64 2,840 (30.1) 8,430 (25.6) 2,806 (30.1) 2,507 (26.9) 7.12
65–74 2,583 (27.3) 9,613 (29.2) 2,572 (27.6) 2,367 (25.4) 4.99
≥75 988 (10.5) 5,728 (17.4) 985 (10.6) 1,226 (13.1) 7.99
Highest level of education, no. (%)b
Illiterate 1,276 (13.5) 5,396 (16.4)
<.001
1,268 (13.6) 1,282 (13.7)
.86
0.44
Elementary school 4,515 (47.8) 15,540 (47.2) 4,465 (47.9) 4,437 (47.6) 0.60
High school 2,797 (29.6) 9,133 (27.7) 2,747 (29.5) 2,785 (29.9) 0.88
College or university and
above
862 (9.2) 2,854 (8.7) 849 (9.1) 825 (8.8) 0.91
Residence, no. (%)b
Urban area 4,394 (46.5) 16,264 (49.4)
<.001
4,354 (46.7) 4,401 (47.2)
.75
1.02
Suburban area 3,976 (42.1) 12,875 (39.1) 3,910 (41.9) 3,886 (41.7) 0.51
Rural area 1,080 (11.4) 3,784 (11.5) 1,065 (11.4) 1,042 (11.2) 0.79
Baseline comorbidity
DCSI, mean (SD)b 1.16 (1.34) 1.15 (1.46) .84 1.16 (1.34) 1.15 (1.45) .72 0.72
DCSI category, no. (%)
0 3,852 (40.8) 14,928 (45.3) <.001 3,803 (40.8) 4,188 (44.9) <.001 8.33
Abbreviations: CIC, chronic illness with complexity index (20); DCSI, diabetes complications severity index (19); NA, not applicable; P4P, pay-for-performance pro-
gram; PSM, propensity score matching.
a Standardized difference was used to compare the balancing for the mean or frequencies of a covariate that were included in the propensity score matching pro-
cess (18). Standardized difference was calculated to evaluate the efficiency of PSM.
b These variables were used in the PSM.
c Baseline antidiabetes drug use was measured if patients were prescribed the selected medications within 1 year before index date; patients could use more than
1 drug.
d Follow-up antidiabetes drug use was measured if patients were prescribed the selected medications between the index date and the study end date (December
31, 2010), cancer occurrence, or death date, whichever came first; patients could use more than 1 drug. This set of variables was not included in the PSM regres-
sion.
e Geographic region categories were based on the branches of the National Health Insurance Administration in which the hospitals were located.
(continued on next page)
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(continued)
Table 1. Patient and Health Care Institution Characteristics Among P4P and Non-P4P Patients With Type 2 Diabetes, Taiwan
Variable
Before PSM Matching After PSM Matching
P4P Non-P4P P Value P4P Non-P4P P Value
Standardized
Difference, %a
1 2,666 (28.2) 7,800 (23.7) 2,631 (28.2) 2,273 (24.4) 8.73
≥2 2,932 (31.0) 10,195 (31.0) 2,895 (31.0) 2,868 (30.7) 0.63
CIC, mean (SD)b 1.10 (0.95) 1.11 (0.98) .08 1.09 (0.95) 1.09 (0.98) .99 0
CIC category, no. (%)
0 2,903 (30.7) 10,258 (31.2)
.13
2,871 (30.8) 2,972 (31.9)
.25
2.33
1 3,567 (37.8) 12,058 (36.6) 3,519 (37.7) 3,437 (36.8) 1.82
≥2 2,980 (31.5) 10,607 (32.2) 2,939 (31.5) 2,920 (31.3) 0.43
Antidiabetes Drug Use at Baseline, No. (%)c
Metforminb
No 2,217 (23.5) 11,127 (33.8)
<.001
2,216 (23.8) 2,191 (23.5)
.67
0.61
Yes 7,233 (76.5) 21,796 (66.2) 7,113 (76.3) 7,138 (76.5) 0.61
Sulfonylureasb
No 1,590 (16.8) 6,373 (19.4)
<.001
1,581 (17.0) 1,601 (17.2)
.70
0.56
Yes 7,860 (83.2) 26,550 (80.6) 7,748 (83.1) 7,728 (82.8) 0.56
Thiazolidinedionesb
No 7,497 (79.3) 28,604 (86.9)
<.001
7,453 (79.9) 7,500 (80.4)
.39
1.25
Yes 1,953 (20.7) 4,319 (13.1) 1,876 (20.1) 1,829 (19.6) 1.25
α Glucosidase inhibitorsb
No 7,982 (84.5) 29,774 (90.4)
<.001
7,928 (85.0) 7,929 (85.0)
.98
0.03
Yes 1,468 (15.5) 3,149 (9.6) 1,401 (15.0) 1,400 (15.0) 0.03
Antidiabetes Drug Use During Follow-up, No. (%)d
Metformin
No 708 (7.5) 4,764 (14.5)
<.001
705 (7.6) 1,092 (11.7)
<.001
NA
Yes 8,742 (92.5) 28,159 (85.5) 8,624 (92.4) 8,237 (88.3) NA
Sulfonylureas
No 854 (9.0) 3,740 (11.4)
<.001
847 (9.1) 972 (10.4)
.002
NA
Yes 8,596 (91.0) 29,183 (88.6) 8,482 (90.9) 8,357 (89.6) NA
Abbreviations: CIC, chronic illness with complexity index (20); DCSI, diabetes complications severity index (19); NA, not applicable; P4P, pay-for-performance pro-
gram; PSM, propensity score matching.
a Standardized difference was used to compare the balancing for the mean or frequencies of a covariate that were included in the propensity score matching pro-
cess (18). Standardized difference was calculated to evaluate the efficiency of PSM.
b These variables were used in the PSM.
c Baseline antidiabetes drug use was measured if patients were prescribed the selected medications within 1 year before index date; patients could use more than
1 drug.
d Follow-up antidiabetes drug use was measured if patients were prescribed the selected medications between the index date and the study end date (December
31, 2010), cancer occurrence, or death date, whichever came first; patients could use more than 1 drug. This set of variables was not included in the PSM regres-
sion.
e Geographic region categories were based on the branches of the National Health Insurance Administration in which the hospitals were located.
(continued on next page)
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(continued)
Table 1. Patient and Health Care Institution Characteristics Among P4P and Non-P4P Patients With Type 2 Diabetes, Taiwan
Variable
Before PSM Matching After PSM Matching




No 4,541 (48.1) 20,708 (62.9)
<.001
4,515 (48.4) 5,279 (56.6)
<.001
NA
Yes 4,909 (52.0) 12,215 (37.1) 4,814 (51.6) 4,050 (43.4) NA
α Glucosidase inhibitors
No 5,035 (53.3) 21,126 (64.2)
<.001
4,998 (53.6) 5,637 (60.4)
<.001
NA
Yes 4,415 (46.7) 11,797 (35.8) 4,331 (46.4) 3,692 (39.6) NA
Health Care Facility Characteristics
Accreditation level, no. (%)b
Medical center 1,915 (20.3) 8,333 (25.3)
<.001
1,915 (20.5) 1,762 (18.9)
.03
4.12
Regional hospital 3,689 (39.0) 8,132 (24.7) 3,584 (38.4) 3,697 (39.6) 2.48
Local hospital 2,172 (23.0) 6,694 (20.3) 2,156 (23.1) 2,140 (22.9) 0.40
Clinic 1,674 (17.7) 9,764 (29.7) 1,674 (17.9) 1,730 (18.5) 1.55
Geographic region, no. (%)b,e
Taipei 2,535 (26.8) 10,068 (30.6)
<.001
2,535 (27.2) 2,584 (27.7)
.65
1.19
Northern 1,263 (13.4) 4,838 (14.7) 1,263 (13.5) 1,304 (14.0) 1.28
Central 3,296 (34.9) 5,361 (16.3) 3,175 (34.0) 3,107 (33.3) 1.54
Southern 852 (9.0) 4,955 (15.1) 852 (9.1) 839 (9.0) 0.49
Kao-Ping 1,269 (13.4) 6,732 (20.5) 1,269 (13.6) 1,284 (13.8) 0.47
Eastern 235 (2.5) 969 (2.9) 235 (2.5) 211 (2.3) 1.70
Abbreviations: CIC, chronic illness with complexity index (20); DCSI, diabetes complications severity index (19); NA, not applicable; P4P, pay-for-performance pro-
gram; PSM, propensity score matching.
a Standardized difference was used to compare the balancing for the mean or frequencies of a covariate that were included in the propensity score matching pro-
cess (18). Standardized difference was calculated to evaluate the efficiency of PSM.
b These variables were used in the PSM.
c Baseline antidiabetes drug use was measured if patients were prescribed the selected medications within 1 year before index date; patients could use more than
1 drug.
d Follow-up antidiabetes drug use was measured if patients were prescribed the selected medications between the index date and the study end date (December
31, 2010), cancer occurrence, or death date, whichever came first; patients could use more than 1 drug. This set of variables was not included in the PSM regres-
sion.
e Geographic region categories were based on the branches of the National Health Insurance Administration in which the hospitals were located.
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P4P Non-P4P P4P, N (%)
Non-P4P, N
(%) P Value P4P Non-P4P
IRR (95%
CI) P Value
No. 9,329 9,329 9,329 9,329 NA NA
Cancer incidence
Overall 59,564 56,790 800 (8.6) 826 (8.9) .50 13.43 14.54 0.92
(0.84–1.02)
.11
Breast 61,144 58,203 54 (1.1) 62 (1.3) .44 0.88 1.07 0.83
(0.56–1.21)
.32
Colorectal 61,050 58,148 112 (1.2) 113 (1.2) .95 1.83 1.94 0.94
(0.72–1.24)
.67
Oral 61,237 58,302 34 (0.4) 35 (0.4) .90 0.56 0.60 0.93
(0.56–1.53)
.75
Liver 61,059 58,124 157 (1.7) 191 (2.1) .07 2.57 3.29 0.78
(0.63–0.97)
.02
Lung 61,216 58,266 76 (0.8) 88 (0.9) .35 1.24 1.51 0.82
(0.60–1.13)
.21
Cervical 61,231 58,307 29 (0.3) 28 (0.3) .90 0.47 0.48 0.99
(0.57–1.72)
.96
Prostate 61,227 58,298 35 (0.4) 34 (0.4) .90 0.57 0.58 0.98
(0.59–1.62)
.93
Stomach 61,254 58,323 44 (0.5) 43 (0.5) .91 0.72 0.74 0.97
(0.63–1.52)
.90




All-cause mortality 61,324 58,389 1,258 (13.5) 2,099 (22.5) <.001 20.51 35.95 0.57
(0.53–0.61)
<.001
Cancer-specific mortality 61,324 58,389 283 (3.0) 347 (3.7) .010 4.61 5.94 0.78
(0.66–0.91)
.002
Diabetes-related mortality 61,324 58,389 541 (5.8) 988 (10.6) <.001 8.82 16.92 0.52
(0.47–0.58)
<.001
Abbreviations: IRR, incidence rate ratio; NA, not applicable; P4P, pay-for-performance program.
a The non-P4P group is the reference group.
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Abbreviations: AGIs, α glucosidase inhibitors; CI, confidence interval; P4P, pay-for-performance program; SUs, sulfonylureas; TZDs, thiazolidinediones.
a Competing risk regression models were used to analyze the effects of P4P and drug effects on risks of cancer incidences while controlling for potential con-
founders: age, sex, highest level of education, rural or urban residence, baseline comorbidity (diabetes complications severity index and chronic illness with com-
plexity), antidiabetes drug use (metformin, SUs, TZDs, AGIs), and health care facility characteristics (accreditation level and geographic regions).
b Nonusers of the drug are the reference group for each drug.
c The non-P4P group is the reference group.
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